View live BRISTOL-MYERS SQUIBB CO chart to track its stock's price action. 1M 1Y 2Y 5Y () News. 0.01; 0.02%; Volume: 8.1 Mil . * q4 earnings per share view $1.42, revenue view $10.73 billion -- refinitiv ibes data. S&P 500. Other BMY Stock News. Should you be buying BMY stock or one of its competitors? Get Bristol-Myers Squibb Co (BMY:NYSE) real-time stock quotes, news, price and financial information from CNBC. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In 2019, for example, it spent $7.3 billion on repurchasing its stock. Co.'s products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. Latest BRISTOL-MYERS SQUIBB COMPANY (BMY) stock news, Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, d... Close. Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing. Bristol Myers Squibb Co (BMY) Stock Quote and News . Volume % Chg: 31%; Get a Leaderboard Chart for BMY? Bristol Myers Squibb Co. on Tuesday said its drug candidate deucravacitinib showed superiority to placebo and to Amgen Inc.'s blockbuster Otezla in a second Phase 3 study in plaque psoriasis. Get (NYE | BMY Bristol-Myers Squibb Company) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report The New York City-based pharmaceutical company logged a loss of $4.45 a share, compared with a loss of 55 cents a share in the year-ago quarter. Search. Bristol Myers stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing. BMY Stock News and Research Articles - Bristol-Myers Squibb Company : latest news, headlines and research articles. It can reflect on the current distribution of Bristol daily returns and investor perception about the current pice of Bristol Myers Squibb as well as its diversification or hedging effects on your existing portfolios. Create watchlists and get real-time prices and news updates for all your watchlist symbols. Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Bristol-Myers Squibb, including Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), and Zoetis (ZTS). View BMY's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Bristol Myers Squibb Co. Thursday logged a fourth-quarter adjusted profit as higher sales of Eliquis and Opdivo, as well as medications it acquired in an acquisition, pushed revenue higher. GET QUOTE $ 59.99. See How IBD Rates . bristol-myers squibb co (bmy): * qtrly revenue $11.07 billion versus $7.95 billion. … Daily Weekly. News; Video; … In the Pharmaceutical Products industry, JNJ , ABT and ZTS are the three stocks most similar to Bristol Myers Squibb Co regarding the price target and analyst recommendation information presented here. Bristol Myers Squibb Says Receives European Commission Approval For Inrebic For Adult Patients With Newly Diagnosed And Previously Treated Myelofirbosis. BMY stock data. Currently there seems to be a trend where … 8 Feb 21. BMY. View the latest Bristol Myers Squibb Co. (BMY) stock price, news, historical charts, analyst ratings and financial information from WSJ. Real time Bristol Myers Squibb (BMY) stock price quote, stock graph, news & analysis. Mail; Finance Home. Stock Advisor Flagship service. join the STCK.PRO community and discover the power of social financial news! For the first quarter ended Dec. 31, adjusted Bristol Myers earnings were $1.46 per share on $11.07 billion in sales. Get all Bristol-Myers Squibb Company (BMY) Dividend News. Home. Mail; News; Sports; Finance; Celebrity; Style; Movies; Weather; Answers; Mobile; Yahoo. Bristol-Myers Squibb Company BMY Morningstar Rating Rating as of Feb 10, 2021. Latest Stock Picks Investing Basics Premium Services. Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated … Bristol-Myers Squibb (BMY Quick Quote BMY - Free Report) closed at $64.83 in the latest trading session, marking a +0.42% move from the prior day. A high-level overview of Bristol-Myers Squibb Company (BMY) stock. Discover the power of Social Financial News! More Technical Analysis News: BMY RSI Chart: About Bristol Myers Squibb Co. Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Real-time … Bristol Myers Squibb – $2 B Incremental Share Repurchase Authorization. Competitors Bristol-Myers Squibb (NYSE:BMY) Vs. JNJ, LLY, PFE, MRK, ABBV, and ZTS. Stock analysis for Bristol Myers Squibb Co (BMY-R) including stock price, stock chart, company news, key statistics, fundamentals and company profile. BMY Stock: Earnings Beat. Find real-time BMY - Bristol-Myers Squibb Co stock quotes, company profile, news and forecasts from CNN Business. Analyzing Bristol-Myers Squibb (NYSE:BMY) stock? Pro users get this 30m faster . Bristol Myers Squibb Co (BMY) - DEVELOPS PHARMACEUTICALS FOR THE TREATMENT OF ONCOLOGY, IMMUNOSCIENCE, CARDIOVASCULAR, AND FIBROTIC DISEASES. Analyzing Bristol-Myers Squibb (NYSE:BMY) stock? GROUP … QQQ 332.75 (-0.23%) AAPL 135.39 ( … * qtrly gaap loss per share $4.45; qtrly non-gaap earnings per share $1.46. Bristol Myers Squibb Co (NYSE:BMY) is a pharmaceutical company. The New York biopharmaceutical company said superiority of deucravacitinib was shown on both co-primary endpoints and multiple key secondary endpoints in the study of patients with … BMY has a greater NA than just about none of of all US stocks. Earnings climbed 20% and sales popped 39%. * ipr&d charge of $11.4 billion included in quarter due to myokardia transaction being accounted for as an asset acquisition. S&P. BMY-R () Stock Market info Recommendations: Buy or sell BMY-R stock? 01-11 stl.news - NEW YORK (STL.News) Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has authorized incremental share repurchases of up to an additional $2 billion of the company’s outstanding shares of common stock. Bristol Myers Squibb is also affirming 2020-2025 long-term financial targets communicated in January 2021: Expects low to mid-single digit revenue CAGR and low double-digit revenue CAGR excluding Revlimid & Pomalyst at constant exchange rates; Expects to maintain low to mid-40s percent non-GAAP operating margin; Expects significant cash flow generation of $45-$50 billion dollars from 2021 -2023. View today's stock price, news and analysis for Bristol Myers Squibb Co. (BMY). In recent years, Bristol Myers has hardly been shy about supporting its share price with buybacks. Find market predictions, BMY financials and market news. Sign up for free alerts to get the latest dividend news on Bristol-Myers Squibb Company (BMY) BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share BRISTOL-MYERS SQUIBB COMPANY | Nyse: BMY | Nyse View BMY's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Return. 609%. Wall Street Stock Market & Finance report, prediction for the future: You'll find the BMY-R share forecasts, stock quote and buy / sell signals below.According to present data BMY-R's BMY-R shares and potentially its market environment have been in bearish cycle last 12 months (if exists). In early August, Bristol Myers and partner Pfizer won a patent fight vs. generic drugmakers over the blood thinner Eliquis. No matching results for '' Tip: Try a valid symbol or a specific company name for relevant results. Co. … Bristol Myers Squibb Co's variance in analysts' estimates is lower than 77.79% of stocks in the large market cap category.